BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with…
Oncology
-
-
MimiVax announces disappointing pivotal Phase IIb trial data for cancer vaccine
The pivotal SURVIVE Phase IIb trial for SurVaxM, a glioblastoma (GBM) peptide-mimic immunotherapeutic cancer vaccine developed by MimiVax, announced interesting…
-
ArriVent’s stock plummets on Phase III NSCLC trial failure
ArriVent BioPharma’s stock has dropped 46% after a Phase III trial of its non-small cell lung cancer (NSCLC) candidate failed…
-
Akeso begins Phase III study of cadonilimab for gastric cancer
Akeso has commenced a global Phase III clinical trial, with the enrolment of the first patient, to evaluate its bispecific antibody,…
-
Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to…
-
Metabolomic signatures strengthen association between diet and cancer risk in women
Cancer is a leading cause of death worldwide, with the World Health Organization (WHO) estimating that cancer accounts for approximately…
-
Roche seeking earlier use for Lunsumio in FL on Phase III data
Roche is seeking a label expansion to use Lunsumio (mosunetuzumab) at an earlier stage after it showed benefit in a…
-
J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC
Johnson & Johnson’s (J&J's) Rybrevant (amivantamab-vmjw) plus chemotherapy has been linked to the longest median overall survival (OS) seen in…
-
Akeso and Summit’s ivonescimab meets OS goals in NSCLC
Akeso and Summit Therapeutics’ ivonescimab has shown further benefit in a first-line non-small cell lung cancer (NSCLC) Phase III study,…
-
Akeso logs Phase III success in second tumour type for ivonescimab
Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter…
